News

Kirsty is biosimiler to Novolog. It is a rapid-acting human insulin analog indicated to improve glycemic control in adults ...
As previously announced, Civica plans to produce three insulin biosimilars – glargine, lispro and aspart – each of which will be available both in vials and prefilled pens, and sell the ...
Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog, expanding their insulin ...
Biocon Biologics expands diabetes portfolio with US FDA approval of Kirsty, an interchangeable rapid-acting insulin aspart in US: Our Bureau, Bengaluru Wednesday, July 16, 2025, 1 ...
Rezvoglar had been approved on December 17, 2021 as a biosimilar, and with this approval joins Semglee (insulin glargine-yfgn), which was the first approved Lantus-interchangeable biosimilar.
The US diabetes market presents a substantial opportunity for Biocon Biologics, with 38.4 million people living with diabetes ...
Biocon share price jumped after its subsidiary Biocon Biologics received USFDA approval for Kirsty, a rapid-acting insulin ...
The US Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin ...
LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM Nov. 07, 2022 6:52 AM ET Lannett Company, Inc. (LCINQ) ...
Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog. This rapid-acting insulin ...
Any such statement, including, but not limited to, the company successfully commercializing the biosimilar insulin glargine, biosimilar insulin aspart and potentially other products in the U.S ...